Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entyvio (vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn's Disease
2016-000678-40Phase 4Completed
- Sponsor
- Takeda
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vedolizumab in autoimmune colitis and Crohn's disease, sponsored by Takeda. Primary endpoint: Safety (adverse events and serious adverse events). Started May 2016; status: completed.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2016-000678-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000678-40.